We further observed that SGLT2 inhibitor use was associated with a reduced risk of mortality regardless of patients’ demographic, tumor characteristics and cancer treatments, despite some associations in sub-groups not reaching statistical significance. This evidence concerns the gene SLC5A2 and cancer.